抑制糖尿病诱导的赖氨酰氧化酶过表达可预防糖尿病视网膜病变相关血管病变
本研究在糖尿病大鼠中探讨减少糖尿病诱导的赖氨酰氧化酶(LOX)过表达对血管细胞凋亡和血视网膜屏障特征的影响。方法采用非糖尿病大鼠、糖尿病大鼠及玻璃体腔注射LOX siRNA或乱序siRNA的糖尿病大鼠,每月注射一次最多三次。结果显示LOX siRNA显著降低视网膜LOX表达,减少无细胞毛细血管和周细胞丢失,并降低视网膜血管通透性。结论提示LOX siRNA玻璃体腔注射可能有效预防糖尿病视网膜病变相关的凋亡和血管渗漏。
要点
- 糖尿病大鼠视网膜LOX表达显著上调,LOX siRNA玻璃体腔注射可显著降低其表达。
- LOX siRNA治疗显著减少糖尿病视网膜的无细胞毛细血管和周细胞丢失。
- LOX siRNA治疗显著降低糖尿病大鼠视网膜血管通透性。
核心结论
- LOX siRNA玻璃体腔注射可能通过抑制糖尿病诱导的LOX过表达,预防糖尿病视网膜病变相关的血管细胞凋亡和血管渗漏。
研究设计与样本
- 研究使用非糖尿病大鼠、糖尿病大鼠及玻璃体腔注射LOX siRNA或乱序siRNA的糖尿病大鼠。
- 糖尿病发病一个月后开始玻璃体腔注射,每月一次,最多三次。
- 研究终点分离视网膜毛细血管网,进行PAS和苏木精染色评估无细胞毛细血管和周细胞丢失,并通过FITC-葡聚糖渗漏评估血管通透性,Western blot检测视网膜LOX水平。
主要发现
- 糖尿病大鼠视网膜LOX表达较非糖尿病大鼠显著上调。
- 注射LOX siRNA的糖尿病大鼠视网膜LOX表达较糖尿病大鼠或乱序siRNA注射大鼠显著降低。
- 糖尿病视网膜无细胞毛细血管和周细胞丢失较非糖尿病视网膜显著增加。
- LOX siRNA治疗的糖尿病大鼠无细胞毛细血管和周细胞计数较未治疗糖尿病大鼠显著减少。
- LOX siRNA治疗的糖尿病大鼠视网膜血管通透性较未治疗糖尿病大鼠显著降低。
临床怎么用
- LOX siRNA玻璃体腔注射可能成为预防糖尿病视网膜病变血管细胞凋亡和血管渗漏的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to investigate the effect of reducing diabetes-induced lysyl oxidase (LOX) overexpression on vascular cell apoptosis and blood-retinal barrier (BRB) characteristics in diabetic rats. METHODS: Nondiabetic rats, diabetic rats, and diabetic rats intravitreally (IV) injected with LOX siRNA or scrambled (scram) siRNA were used in the study. One month after the onset of diabetes, intravitreal injections were initiated at monthly intervals for up to three times. At the end of study, retinal capillary networks were isolated, stained with periodic acid-Schiff (PAS) and hematoxylin, and assessed for acellular capillaries (AC) and pericyte loss (PL). To assess vascular leakage, extravasation of FITC-dextran was evaluated in retinal capillaries after tail vein injection of FITC-dextran. Western blot analysis was performed to determine retinal LOX level and confirm LOX downregulation via LOX siRNA intravitreal injection. RESULTS: LOX expression was significantly upregulated in retinas of diabetic rats compared with that of nondiabetic rats. Diabetic rats injected with LOX siRNA showed a significant decrease in retinal LOX expression compared with those of diabetic rats or scram siRNA-injected rats. In diabetic retinas, AC and PL were significantly increased compared with those of nondiabetic retinas. Importantly, diabetic rats treated with LOX siRNA exhibited a significant decrease in AC and PL counts compared with those of untreated diabetic rats. Furthermore, diabetic rats treated with LOX siRNA showed significant decrease in retinal vascular permeability compared with that of untreated diabetic rats. CONCLUSIONS: Findings suggest LOX siRNA intravitreal injection may be effective against diabetes-induced LOX overexpression in preventing apoptosis and vascular leakage associated with diabetic retinopathy.
引用
- Song B, Kim D, Nguyen NH, et al. Inhibition of Diabetes-Induced Lysyl Oxidase Overexpression Prevents Retinal Vascular Lesions Associated With Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2018. PMID: 30550614. doi:10.1167/iovs.18-25543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。